Clinical Data Amgen scores with new thyroid eye disease formulation PharmaphorumCan Amgen's subcutaneous version of Tepezza inject renewed growth into the thyroid eye disease blockbuster?Clinical DataOphthalmologyRead full story pharminent April 7, 2026 (Last updated: April 8, 2026) Pharmaphorum Can Amgen’s subcutaneous version of Tepezza inject renewed growth into the thyroid eye disease blockbuster? Clinical DataOphthalmologyRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: FDA floats new clinical trial reforms; Takeda punts Denali brain drugNext: Amgen Seeks ‘Return to Growth’ for Tepezza as More Convenient Formulation Aces Phase 3 Related Stories Clinical Data AstraZeneca, Ionis drug fails big heart disease study in major setback pharminent July 9, 2026 Clinical Data Roche’s KRAS drug tops its rivals in lung cancer trial pharminent July 2, 2026 Clinical Data EAN 2026: Real-world data supports safety and efficacy of AbbVie’s Vyalev in Parkinson’s pharminent July 1, 2026
